Cadaver fat from organ and tissue donors is being used for cosmetic procedures such as Brazilian butt lifts and breast enhancements, and it is legal in the United States. Products like AlloClae and Renuva, derived from donated human adipose tissue, have been on the market for over a year, sparking debates about the ethical implications of using human remains for aesthetic purposes.
The use of cadaveric materials in medicine is not new; skin grafts and rib grafts from donors have long been used for reconstructive surgery. However, the repurposing of donated fat, which was previously discarded, for cosmetic fillers is a relatively recent development. Renuva, developed by tissue bank MTF Biologics, can be injected to plump cheeks, temples, and other areas, and it integrates with the recipient's own tissue over time.
AlloClae, a product from Tiger Aesthetics, is thicker and more suitable for body procedures like butt lifts and breast augmentations. Unlike autologous fat transfer, which requires liposuction from the patient, these cadaver-derived fillers offer a quicker, less invasive option with no downtime. This convenience has attracted patients, particularly those on weight-loss drugs like Ozempic who lack sufficient body fat for transfer.
In the US, the Uniform Anatomical Gift Act authorises tissue banks to collect donations for transplant and research, and the FDA has cleared these products for use. Despite the macabre nature, many patients are unfazed, prioritising convenience over the source of the material. However, ethical concerns persist, particularly among registered donors who may not have consented to cosmetic use of their remains.
